Elecoglipron
Investigational drug
From Wikipedia, the free encyclopedia
Elecoglipron is an investigational new drug that is being developed by Eccogene and AstraZeneca for the treatment of obesity, type 2 diabetes mellitus, and liver disorders. It is a glucagon-like peptide-1 receptor agonist. [1][2][3]
| Clinical data | |
|---|---|
| Other names | AZD-5004; ECC-5004 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C48H46F2N10O5 |
| Molar mass | 880.958 g·mol−1 |
| 3D model (JSmol) | |
| |
| |